NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Phanes Therapeutics

Phanes Therapeutics

Private
San Diego, CaliforniaHealthcare & Life Scienceshttps://www.phanesthera.com/

Last Round

Series B

May 25, 2021

Total Funding Raised

$40M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Phanes Therapeutics is a biotechnology company specializing in drug discovery and early development in immuno-oncology, creating native IgG-like bispecific antibodies that improve drug-like properties to facilitate patient access to innovative therapies.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

bispecific antibodymonoclonal antibodyimmuno-oncologyclinical-stage biotechdrug discoverybiopharmaclinical trialantibody engineeringoncology therapeuticslicensing agreementbiotech pipelinepancreatic cancer treatmentR&D collaborationprotein engineering

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Phanes Therapeutics Comparables

Compare Phanes Therapeutics with similar companies based on industry and business-model similarity.

Phanes Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Chimagen Biosciences
84%
Qure Biotechnology (Shanghai) Co., Ltd.
78%
APITBIO, Inc.
77%

Phanes Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BMay 25, 2021
Series ANov 1, 2018

Phanes Therapeutics Investors

Notable investors and investment history

Phanes Therapeutics investors
InvestorRounds
DYEE CapitalSeries B
险峰K2VCSeries B, Series A
Delos Capital PartnersSeries B
Volcanics VentureSeries B
HongShan Capital Group (HSG)Series B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 22, 2026

    Updated Phase 2 results for spevatamig to be presented at ASCO Annual Meeting.

  • Mar 18, 2026

    Presenting three clinical posters at AACR 2026.

Phanes Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Phanes Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Phanes Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersSan Diego, California
Employee Range29
Year Founded2016
Last FundingMay 25, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.